Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Active not recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Plasma cell 1

Conditions

Leukemia, Myeloid, Acute 32Myelodysplastic Syndromes 28Multiple Myeloma 27Precursor Cell Lymphoblastic Leukemia-Lymphoma 26Hodgkin Disease 12Leukemia, Myelogenous, Chronic, BCR-ABL Positive 11Lymphoma, Non-Hodgkin 10Lymphoma 10Hematologic Neoplasms 10Neuroblastoma 9Myeloproliferative Disorders 9Anemia, Refractory, with Excess of Blasts 8Lymphoma, Mantle-Cell 7Leukemia, Myelomonocytic, Chronic 7Leukemia 7Neoplasms, Plasma Cell 6Lymphoma, T-Cell 6Leukemia, Biphenotypic, Acute 6Graft vs Host Disease 6Leukemia, Lymphocytic, Chronic, B-Cell 5Burkitt Lymphoma 5Recurrence 4Primary Myelofibrosis 4Melanoma 4Lymphoma, Large B-Cell, Diffuse 4Lymphoma, Follicular 4Leukemia, Myelomonocytic, Juvenile 4Hematologic Diseases 4Ganglioneuroblastoma 4Anemia, Aplastic 4

Interventions

Lenalidomide 7Dexamethasone 5daratumumab 4Calcium Dobesilate 4dexamethasone acetate 3dexamethasone 21-phosphate 3auricularum 3Curcumin 3isatuximab 2iberdomide 2Leflunomide 2pomalidomide 1poly ICLC 1piperine 1pembrolizumab 1ixazomib 1fludarabine phosphate 1fludarabine 1citarinostat 1Watchful Waiting 1Urination 1Stem Cell Transplantation 1Resistance Training 1Propranolol 1Probiotics 1Peripheral Blood Stem Cell Transplantation 1PVX-410 vaccine 1Observation 1Metformin 1Melphalan 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Smoldering Multiple Myeloma × Melphalan × 1 year × Clear all
NCT00114101 2026-05-29

Lenalidomide in Treating Patients With Multiple Myeloma Undergoing Autologous Stem Cell Transplant

National Cancer Institute (NCI)

Phase 3 Active not recruiting
460 enrolled 11 charts
Plasma cell

Smoldering Multiple Myeloma, Multiple Myeloma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡